Why Progyny (PGNY) Might be Well Poised for a Surge
Progyny (PGNY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
PGNY - Progyny, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$30.00
DETAILS
HIGH:
$35.00
LOW:
$27.00
MEDIAN:
$30.00
CONSENSUS:
$30.00
DOWNSIDE:
2.12%
Stock News
Are You Looking for a Top Momentum Pick? Why Progyny (PGNY) is a Great Choice
Does Progyny (PGNY) have what it takes to be a top stock pick for momentum investors? Let's find out.
What Makes Progyny (PGNY) a New Strong Buy Stock
Progyny (PGNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
What Does the Sale of Progyny Shares by the CFO Mean for Investors?
CFO Mark Livingston sold 8,275 shares for a transaction value of ~$211,000 on May 20, 2026. This represented 9.47% of Livingston's direct holdings, reducing his direct position to 79,063 shares.
A Look at Progyny Inc (PGNY) After 3.8% Gain -- GF Value $28.04 vs Price $26.63
On June 12, 2026, Progyny Inc (PGNY) shares rose 3.8% to $26.63. The stock has traded within a 52-week range of $16.10 to $28.75, indicating considerable volati
A Progyny (PGNY) Insider Sold 5,500 Shares for $137,000
Progyny delivers fertility benefits to major employers; a key insider recently trimmed their stake, according to SEC filings.
New Progyny Study Shows Growing Demand for Human Guidance in an Increasingly Digital Healthcare System
Patients increasingly say human connection and advocacy are essential to reducing stress and improving the care experience Patients increasingly say human connection and advocacy are essential to reducing stress and improving the care experience
Progyny, Inc. Announces Share Repurchase Program
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that its Board of Directors has approved a share repurchase program to repurchase up to $200 million of its common stock. The program will be funded through available cash balances.
Progyny Inc (PGNY) Stock Down 3.8% -- Now Undervalued? GF Score: 87/100
On May 21, 2026, Progyny Inc (PGNY) shares fell 3.8%, closing at $24.69. This decline comes amidst a 52-week range where the stock has seen a high of $28.75 and
Progyny, Inc. (PGNY) Shareholder/Analyst Call Transcript
Progyny, Inc. (PGNY) Shareholder/Analyst Call Transcript
Bull of the Day: Progyny (PGNY)
For growth investors seeking exposure to a differentiated healthcare disruptor with strong secular tailwinds, Progyny (PGNY) stock deserves a close look.
Progyny, Inc. (PGNY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Progyny, Inc. (PGNY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
3 Highly Ranked Medical Stocks to Buy Now: DVA, GMED, PGNY
These highly ranked medical stocks have been capitalizing on their sales expansion, and their defensive or secular growth profiles could become even more attractive if an economic downturn emerges.
Progyny, Inc. to Present at BofA Securities 2026 Health Care Conference
NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that Progyny's Chief Executive Officer, Pete Anevski, and Chief Financial Officer, Mark Livingston, will participate in a fireside chat at the BofA Securities 2026 Health Care Conference on Tuesday, May 12, 2026, at 11:20 A.M. Pacific Time / 2:20 P.M. Eastern Time.
Progyny Q1 Earnings Call Highlights
Progyny NASDAQ: PGNY reported what management called a strong start to 2026, with first-quarter revenue reaching a record level and profitability exceeding expectations amid continued investments in its platform and member experience.
Progyny, Inc. (PGNY) Q1 2026 Earnings Call Transcript
Progyny, Inc. (PGNY) Q1 2026 Earnings Call Transcript
Progyny (PGNY) Q1 Earnings and Revenues Beat Estimates
Progyny (PGNY) came out with quarterly earnings of $0.5 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.48 per share a year ago.
Progyny, Inc. Announces First Quarter 2026 Results
Reports Record First Quarter Revenue of $328.5 MillionEarly Selling Season Activity Reflects Robust Demand for Women's Health and Family Building SolutionsReturned Value to Shareholders Through Repurchase of 8.8 Million Shares to Date Since November NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the “Company”), a global leader in women's health and family building solutions, today announced its financial results for the three-month period ended March 31, 2026 (“the first quarter of 2026”), as compared to the three-month period ended March 31, 2025 (“the first quarter of 2025” or “the prior year period”). “We're pleased with the strong start to the year, as member engagement trended to the higher end of our expectations, reflecting that people are pursuing the services they need in order to address their family building and overall health and well-being goals,” said Pete Anevski, Chief Executive Officer of Progyny.
Should Value Investors Buy Progyny (PGNY) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Progyny (PGNY) Upgraded to Buy: Here's Why
Progyny (PGNY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Price Targets
Progyny price target raised to $35 from $30 at KeyBanc
$35.00
(was $30.65)
KeyBanc
Progyny upgraded to Buy from Hold at Canaccord
$30.00
(was $24.05)
Canaccord Genuity
Progyny price target raised to $27 from $23 at Barclays
$27.00
(was $23.25)
Barclays
Progyny (PGNY) PT Lowered to $30 at Jefferies
$30.00
(was $17.79)
Brian Tanquilut
·
Jefferies
Progyny (PGNY) PT Lowered to $28 at Truist Securities
$28.00
(was $17.69)
Jailendra Singh
·
Truist Financial
Progyny price target raised to $35 from $30 at BTIG
$35.00
(was $25.28)
J.P. Morgan
Progyny upgraded to Buy from Hold at Truist
$34.00
(was $28.23)
Jailendra Singh
·
Truist Financial
Progyny price target raised to $32 from $30 at KeyBanc
$32.00
(was $26.80)
Scott Schoenhaus
·
KeyBanc
Progyny initiated with an Overweight at Barclays
$29.00
(was $24.70)
Peter Warendorf
·
Barclays
KeyBanc upgrades Progyny to Overweight on 'emerging' catalysts
$30.00
(was $23.81)
KeyBanc
Cantor Fitzgerald Reiterates Overweight Rating on Progyny (PGNY)
$28.00
(was $22.22)
Sarah James
·
Raymond James
Progyny price target raised to $27 from $24 at Truist
$27.00
(was $23.05)
Jailendra Singh
·
Truist Financial
Progyny price target raised to $23 from $17 at Canaccord
$23.00
(was $22.53)
Canaccord Genuity
Progyny (PGNY) PT Lowered to $19 at Jefferies
$19.00
(was $21.61)
Glen Santangelo
·
Jefferies
Progyny (PGNY) PT Lowered to $22 at Cantor Fitzgerald
$22.00
(was $21.61)
Sarah James
·
Cantor Fitzgerald
Truist Securities Downgrades Progyny (PGNY) to Hold
$19.00
(was $21.61)
Jailendra Singh
·
Truist Financial
Progyny (PGNY) PT Lowered to $18 at Canaccord Genuity
$18.00
(was $16.46)
Richard Close
·
Canaccord Genuity
Progyny (PGNY) PT Lowered to $22 at BofA Securities
$22.00
(was $16.46)
Michael Cherny
·
Bank of America Securities
Jefferies lowers Progyny price target to $24, calls selloff 'excessive'
$24.00
(was $16.55)
Glen Santangelo
·
Jefferies
Progyny (PGNY) PT Raised to $33 at Truist Securities
$33.00
(was $17.78)
Jailendra Singh
·
Truist Financial